Drug Profile


Alternative Names: CHR-2797

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Azienda Ospedaliera Ospedali Riuniti Marche Nord; CTI BioPharma
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 09 Dec 2017 Interim efficacy and adverse events data from a phase II trial in Myelodysplastic syndrome presented at 59th Annual Meeting and Exposition of the American Society of Hematology
  • 25 Oct 2017 Weill Medical College of Cornell University and CTI BioPharma completes phase II trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (NCT02452346)
  • 03 Feb 2017 Leukaemia and Lymphoma Research Institute and National Cancer Research Institute terminates the AML-LI-1 trial in Acute myeloid leukaemia and Myelodysplastic syndrome (Combination therapy, First line therapy, In elderly) in United Kingdom and Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top